Navigation Links
Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
Date:3/8/2013

DALLAS, March 8, 2013 /PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a U.S. Company specializing in cannabinoid formulation-based health solutions through its Phytiva brand product lines is pleased that in the last two days, medical cannabis bills have easily advanced out of key committees to full votes in both the Illinois General Assembly and the New Hampshire House of Representatives.  These actions toward providing safe access to medical cannabis for people with unmet medical needs in both Illinois with House Bill 0030 and New Hampshire with House Bill 442-FN continue the trend of state-by-state recognition of the medical value of cannabis and cannabinoids.

Currently 18 states and the District of Columbia have enacted laws which approve and regulate the use medical cannabis, two of which are considering expansion of existing law.  In addition to Illinois and New Hampshire, another 17 states have pending legislation to enact a form of legal protection for medicinal cannabis patients.  Recent national polls show that approximately 80% of Americans are in favor of medicinal cannabis legalization.

"We are incredibly encouraged that more than two-thirds of U.S. states have adopted laws or are formally considering bills to help patients in need of medical cannabis for their ailments.  We commend the most recent bipartisan developments in Illinois and New Hampshire.  As more and more jurisdictions provide legal safe access frameworks, the Company intends to enter these markets, not only in the United States but also abroad, with its Phytiva brand product lines," stated Robert Kane , President and CEO of X-Change Corp.

About Phytiva Brand Product Lines

Phytiva expects to develop and launch various innovative product lines.  The first is the Phytiva Brand European Line, which is an inventive line that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a cannabinoid based product line, utilizing the unique and potent benefits of cannabinoids.  Phytiva's revolutionary formulations target not just the symptom, but also the cause.  Cannabinoids and their sources constitute an ideal base for therapeutic solutions and have been utilized for centuries in skin and other remedies for human ailments.

About The X-Change Corporation

X-Change Corp. is a U.S. Company specializing in cannabinoid based extracts and products that target medical cannabis, nutraceutical, cosmeceutical, and social usage solutions through multiple Phytiva Brand product lines, products, and services. These new Phytiva lines will be launched with cannabinoid based formulations through the launching of a combination of retail and wholesale products, medical cannabis dispensaries, cannabis research in clinics and laboratories, and other legal state and foreign grow operations, on a jurisdiction by jurisdiction approved basis.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

X-Change Corp.

President & CEO

Robert Kane

info@phytiva.com

www.phytiva.com

1.866.326.5595


'/>"/>
SOURCE X-Change Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Biosimilars: A return to optimism?
2. Revenue Growth Optimism in Pharmaceutical Industry: 2013 Survey Reports at RnRMarketResearch.com
3. Rapid Fire Marketing: CANNAcig to Sponsor Medical Cannabis Cup 2012 in San Francisco
4. Cannabis Science Gets Set to Release "Phytiva" Its Newest Brand of Over-the-Counter Skin and Nutraceutical Product Lines Through its Newest Venture Phytiva Pharmaceuticals Inc.
5. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
6. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
7. New Study Shows Cannabis Effects on Driving Skills
8. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Phreesia identifies over 26% of patients who require additional autism evaluation
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, Inc. ... (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to ... for the treatment of bacterial infections including those ... recognized as an attractive antibacterial target for more ... of suitable chemical starting points has hampered its ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
Breaking Medicine News(10 mins):